Controlled Release Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Controlled Release Technologies

Catalent is the global leader in advanced drug technologies, providing tablets, capsules and other formulations for sustained/modified drug substance release, launching more than 50 products into all the major markets.

Catalent matches each project with a competent, enthusiastic team, to ensure all work is performed according to customers’ timelines and budget. Whether a controlled-release technology is needed to manage a product’s lifecycle in the marketplace, or for a specific clinical, pharmacodynamics, or pharmacokinetic profile, Catalent can help to achieve the desired outcome.

In 2014 Catalent will celebrate 80 years of softgel manufacturing and has continually delivered innovation with specialised global manufacturing and innovative technological enhancements such as chewable softgels and enteric coatings, to enable delayed-release of the active ingredient with targeted absorption.

Further technology advancements in controlled release include Catalent’s OSDrC® OptiDoseTM technology, which enables design of dividable, multi-layer, single or multi-core tablets with a variety of core numbers, shapes, sizes, and placement. The flexible-core capability provides new alternatives in controlled release designs for drug formulators, developers, and marketers in a high quality, one step manufacturing process.  This expands tableting capabilities in many areas that differentiate beyond existing technologies.

OptiDose technology enables single or multiple APIs in a single tablet, with different release profiles. With shown improvement in mass variability between layers, OptiDose offers tablet design to minimise cross-layer interaction and improved product stability.

 

Catalent Pharma Solutions
Website: www.catalent.com

E-mail: info@catalent.com 
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here